Supplementary Figure 2. Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy
figureposted on 2021-04-14, 10:19 authored by David Stenehjem, Solomon Lubinga, Keith A Betts, Wenxi Tang, Mads Jenkins, Yongqin YuanYongqin Yuan, John Hartman, Sumati Rao, Jenny LamJenny Lam, David WaterhouseDavid Waterhouse
Sankey diagram of treatment patterns for patients initiating 1L therapy between August to December 2018 (A), January to June 2019 (B) and July to December 2019 (C). 1L: first-line; 2L: second-line; 3L: third-line; Nivo: nivolumab; Pembro: pembrolizumab.